Daniel Rosebrock
Impact in
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Cancer Genomics and Diagnostics 29
- Cancer-related molecular mechanisms research 1
- Genetics 9
- Chronic Lymphocytic Leukemia Research 8
- Genomic variations and chromosomal abnormalities 5
- Co-authors
- Gad A. Getz (7 shared papers)Dimitri G. Livitz (5 shared papers)Julian M. Hess (2 shared papers)Nicholas J. Haradhvala (2 shared papers)Paz P Polak (2 shared papers)Jaegil Kim (2 shared papers)Ayellet V. Segrè (1 shared paper)Philip A. Branton (1 shared paper)
- Journals
- Nature Communications (15 papers)Nature (7 papers)Nature Genetics (6 papers)Blood (3 papers)Nature Biotechnology (3 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Daniel Rosebrock
51 papers receiving 14.7k citations
Daniel Rosebrock's Hit Papers
Peers
Comparison fields: 5 of 128
- Cancer Research 5.1k
- Oncology 2.6k
- Pathology and Forensic Medicine 1.6k
- Genetics 702
- Molecular Biology 3.8k
Countries citing papers authored by Daniel Rosebrock
This map shows the geographic impact of Daniel Rosebrock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rosebrock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rosebrock more than expected).
Fields of papers citing papers by Daniel Rosebrock
This network shows the impact of papers produced by Daniel Rosebrock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rosebrock. The network helps show where Daniel Rosebrock may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Rosebrock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2401 |
| 2 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2169 |
| 3 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes Hit paper breakdown → | 2018 | 1462 |
| 4 | Resistance to checkpoint blockade therapy through inactivation of antigen presentation Hit paper breakdown → | 2017 | 799 |
| 5 | Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors Hit paper breakdown → | 2017 | 758 |
| 6 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 730 |
| 7 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 564 |
| 8 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Hit paper breakdown → | 2020 | 489 |
| 9 | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes Hit paper breakdown → | 2020 | 428 |
| 10 | A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer Hit paper breakdown → | 2017 | 390 |
| 11 | RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues Hit paper breakdown → | 2019 | 383 |
| 12 | Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes Hit paper breakdown → | 2021 | 362 |
| 13 | Comprehensive molecular characterization of mitochondrial genomes in human cancers Hit paper breakdown → | 2020 | 319 |
| 14 | Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition Hit paper breakdown → | 2020 | 315 |
| 15 | Genomic basis for RNA alterations in cancer Hit paper breakdown → | 2020 | 310 |
| 16 | The landscape of viral associations in human cancers Hit paper breakdown → | 2020 | 293 |
| 17 | 2019 | 288 | |
| 18 | 2020 | 223 | |
| 19 | 2018 | 207 | |
| 20 | 2020 | 190 |
About Daniel Rosebrock
Daniel Rosebrock is a scholar working on Cancer Research, Genetics, Genetics, Molecular Biology and Oncology, having authored 51 papers that have together received 14.8k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (29 papers), Chronic Lymphocytic Leukemia Research (8 papers), Genomic variations and chromosomal abnormalities (5 papers), Single-cell and spatial transcriptomics (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Chromatin Remodeling and Cancer (2 papers), Cancer-related molecular mechanisms research (1 paper) and Cervical Cancer and HPV Research (1 paper). The work is most often cited by research in Cancer Research (5.1k citations), Oncology (2.6k citations), Pathology and Forensic Medicine (1.6k citations), Genetics (702 citations) and Molecular Biology (3.8k citations). Daniel Rosebrock has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Gad A. Getz, Dimitri G. Livitz, Julian M. Hess, Nicholas J. Haradhvala, Paz P Polak, Jaegil Kim, Ayellet V. Segrè, Philip A. Branton, Hailei Zhang and Kristin Ardlie. Their work appears in journals such as Nature Communications, Nature, Nature Genetics, Blood and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.